SOLENO THERAPEUTICS INC

SLNO - CIK 0001484565

Market cap$2.76 B

Rank#1877

SEC filings1,119

SOLENO THERAPEUTICS INC trades as SLNO and has a market capitalization of $2.76 B, making it the #1877 largest US-listed company by market value. In its fiscal 2016 annual report the company posted revenue of $1.45M, up 138.8% from the prior year and net income of $20.89M. This page tracks SOLENO THERAPEUTICS INC through 1,119 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.45MFY 2016

Net income (latest FY)$20.89MFY 2025

Operating cash flow (latest FY)$46.80MFY 2025

Total assets (latest FY)$563.83MFY 2025

Gross margin-4.0%latest FY

Financial performance

SLNO annual revenueView details

SLNO annual net incomeView details

Key statistics

Market cap: $2.76 B
Share price (derived)market cap / shares outstanding: $53.01
P/E ratio (trailing FY): 132.3
EPS (diluted)FY 2025: $0.39
Shares outstandingas of 2026-04-30: 0.05B
Total equityas of 2026-03-31: $495.80M
Return on equity: 4.2%
Long-term debtas of 2026-03-31: $49.87M

Latest filings

Filing	Type	Filed
POS AM	-	2026-05-21
AW	-	2026-05-21
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18

Browse the full filing history (1,119 filings)

Recent press releases

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio2026-04-06
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio | Soleno Therapeutics Inc.
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer2026-02-26
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer | Soleno Therapeutics Inc.
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR2026-02-25
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR | Soleno Therapeutics Inc.
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET2026-02-11
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life .
Soleno Therapeutics to Participate in Upcoming Conferences2026-01-29
Soleno Therapeutics to Participate in Upcoming Conferences | Soleno Therapeutics Inc.

Similar companies

The largest companies sharing SOLENO THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T SLNO vs LLY

JNJJohnson & Johnson$573.98 B SLNO vs JNJ

ABBVAbbVie Inc.$399.47 B SLNO vs ABBV

MRKMerck & Co., Inc.$293.16 B SLNO vs MRK

AZNAstraZeneca PLC$286.27 B SLNO vs AZN

Frequently asked questions

What is SOLENO THERAPEUTICS INC's market cap?

SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of $2.76 B as of 2026-06-10, ranking #1877 among US-listed companies.

How much revenue does SOLENO THERAPEUTICS INC make?

SOLENO THERAPEUTICS INC reported revenue of $1.45M for fiscal year 2016, an increase of 138.8% year over year.

Is SOLENO THERAPEUTICS INC profitable?

Yes. SOLENO THERAPEUTICS INC reported net income of $20.89M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.